Medipost’s Pneumostem gets FDA’s fast-track designation

Korea Biomedical Review

23 August 2019 - Medipost said that the U.S. FDA has given a fast- track designation for Pneumostem, a bronchopulmonary dysplasia treatment for preterm infants.

The fast-track designation comes after the FDA gave an orphan drug designation for the drug in 2014. 

The company has also completed phase 1 and 2 clinical trials in the U.S. in January this year.

Read Korea Biomedical Review article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Fast track